Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/20846
Title: Going nuclear - It is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team.
Authors: Murphy, Declan G;Hofman, Michael S;Azad, Arun;Violet, John;Hicks, Rodney J;Lawrentschuk, Nathan
Affiliation: Department of Surgery, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia
Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Sir Peter MacCallum, Department of Oncology, The University of Melbourne, Victoria, Australia
Molecular Imaging and Nuclear Medicine Therapeutics, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Division of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Issue Date: 24-May-2019
EDate: 2019-05-24
Citation: BJU International 2019; online first: 24 May
Abstract: The value of a multidisciplinary approach to the management of prostate cancer (PC) is widely appreciated by both health care professionals and patients alike. Whether for the navigation of localised PC where management options can be perplexing, or the management of advanced prostate cancer where therapy options are evolving rapidly, and clinical trial options abound, it is best practice that patients are offered multidisciplinary options[1]. This may include the presence of health care practitioners of various types in a physical multidisciplinary clinic, or having a virtual network whereby patients can access multidisciplinary care in different environments. Importantly, a well-run multidisciplinary team (MDT) meeting is the key to anchoring such care and considering all multidisciplinary options for prostate cancer patients. Indeed, this approach is mandated by law in the UK where multidisciplinary care was enshrined in the Health Care Act based on the Improving Outcome Guidance work which underpins cancer care in the National Health Service in the UK. This article is protected by copyright. All rights reserved.
URI: http://ahro.austin.org.au/austinjspui/handle/1/20846
DOI: 10.1111/bju.14814
ORCID: 0000-0001-8553-5618
PubMed URL: 31127664
Type: Letter
Subjects: #PCSM
177Lu-PSMA-617
Lutetium
Neoplasm metastasis
PSMA protein
Prostate neoplasm
Radioimmunotherapy
Theranostic Nanomedicine
ligands
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.